Picton Mahoney Asset Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Picton Mahoney Asset Management’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-72	Closed	-$18K	–	984
2025 Q1	$18K	Sell	72 -26	-27%	-$7.82K	﹤0.01%	592
2024 Q4	$32K	Buy	98 +35	+56%	+$11.9K	﹤0.01%	427
2024 Q3	$21K	Buy	63 +31	+97%	+$9.85K	﹤0.01%	412
2024 Q2	$8K	Buy	+32	New	+$9.31K	﹤0.01%	487
2023 Q1	–	Sell	-354	Closed	-$149K	–	518
2022 Q4	$149K	Buy	+354	New	+$143K	0.01%	479

Other funds holding BIO

First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

FPA

First Pacific Advisors El Segundo, California $7.14B AUM 21.51% 1-Year Est. Return

Picton Mahoney Asset Management's BIO Position: Q2 2025 in Review

Picton Mahoney Asset Management sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2025, closing a stake of 72 shares — an estimated $18K sold.

Picton Mahoney Asset Management first reported a position in BIO in Q4 2022 and held it in 5 quarters. The position peaked at $149K in Q4 2022. 384 funds tracked by Wall St. Rank hold BIO as of Q2 2025.

Picton Mahoney Asset Management reported no remaining Bio-Rad Laboratories Class A position as of Q2 2025 after selling out during the quarter.
Picton Mahoney Asset Management sold 72 Bio-Rad Laboratories Class A shares in Q2 2025, an estimated $18K.
Picton Mahoney Asset Management first reported a position in Bio-Rad Laboratories Class A in Q4 2022 and held it in 5 quarters.
Picton Mahoney Asset Management's Bio-Rad Laboratories Class A position peaked at $149K in Q4 2022.
384 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2025.

Based on Picton Mahoney Asset Management's 13F filing for Q2 2025, filed 12 Aug 2025.